In the NDF research report it says "While Patrys has yet to...

In the NDF research report it says

"While Patrys has yet to choose an initial indication for its Deoxymab products, glioblastoma looks
particularly interesting given the role radiation therapy has in the current standard of care, and the
demonstrated ability of Deoxymab to act as a radiosensitiser. Glioblastoma, an Orphan indication,
is potentially a billion-dollar market opportunity ..."

"Patrys has flagged that its first indication may be an Orphan one, and James Hansen has in the past
studied glioblastoma. The latter cancer could be a billion-dollar opportunity despite the relatively small patient population, and allow Patrys to move towards late stage clinical studies reasonably swiftly."

"Coming behind Telazoparib is BGB-290 from a Chinese/American biotech company called BeiGene. That drug candidate, now in Phase 1, has as one of its key competitive advantages a better brain penetration profile compared to the other PARP inhibitors."

Given Glioblastoma is potentially a big market opportunity, PAT-DX1, radiotherapy, and BGB-290 could be a golden combination against brain cancer and might lead to a huge win-win success. Wish to see "Ann: PAT-DX1 is synergistic with BGB-290" someday in the not-too-distant future.